For most of the last century, a diagnosis of Alexander disease came with a precise account of what was destroying a child’s brain and nothing at all to do about it. That ended on September 3, when the FDA approved Zanvastro (zilganersen), the first therapy ever cleared for the disease, for pediatric and adult patients alike. It arrived from Ionis Pharmaceuticals more than two weeks ahead of its decision date, and it goes after the cause rather than the symptoms.
It also lists at $285,000 a dose, four doses a year, roughly $1.14 million in annual list price for a U.S. population the company itself puts at about 300 patients. And the approval came bundled with a second asset the celebratory coverage mostly skipped: a rare pediatric disease priority review voucher, a transferable coupon that lets its holder skip the FDA queue on a future drug and that has lately resold for $150 million or more. A fatal childhood disease finally has a medicine, and the same government paperwork that cleared it worked exactly as the orphan-drug economy was built to work.
Start with the cell that goes wrong, because it explains both the disease and, for the first time, the drug. Astrocytes are the brain’s support scaffolding, and inside them sits a structural protein called glial fibrillary acidic protein, or GFAP. In Alexander disease a mutation in the GFAP gene, usually arising spontaneously rather than passed down from a parent, drives the protein to accumulate to toxic levels. It clumps into deposits called Rosenthal fibers, the white matter that insulates the brain’s wiring breaks down, and a child begins losing milestones already reached: walking, speech, the ability to swallow. The infantile form kills early.
The tool is an antisense oligonucleotide, a short engineered strand of genetic material that binds the GFAP messenger RNA and marks it for destruction before the cell can read it into protein. Ionis has spent two decades building this chemistry, and the contrast with its most famous success is the clean way to see what zilganersen does. Spinraza, the antisense drug that in 2016 became the first to change the course of a fatal pediatric neurodegenerative disease, spinal muscular atrophy, works by coaxing cells to make more of a protein they lack. Alexander disease is the reverse problem, a toxic surplus, so zilganersen turns the volume down instead of up. The company’s record with the approach is mixed: Qalsody, its 2023 antisense drug for a genetic form of ALS, reached the market largely on a biomarker after its main clinical endpoint fell short.
Zilganersen looks sturdier than that. The pivotal trial (NCT04849741) randomized 49 patients aged two and up, with a small substudy in children under two. At week 61, treated patients five and older held their walking speed on a 10-meter walk test while the untreated comparison group declined, and children aged two to four gained gross motor skills as controls slipped. Blood tests confirmed the drug was hitting its target. Those are clinical outcomes, children who kept walking, not only a lab value moving the right way. In a disease that had zero options, that counts.
It is also 49 people followed for a little over a year, dosed by injection into the spinal fluid every three months by a trained clinician, with vomiting, back pain, cough, and occasional aseptic meningitis among the side effects. Whether the gait benefit holds at three years, or five, the data cannot yet say, because they do not run that long. At $1.14 million a year that uncertainty stops being academic: the extension studies, not the approval, will decide whether the price bought a course correction or an expensive delay.
The price itself follows the orphan-drug logic exactly. William Blair’s Myles Minter called it above expectations but predicted little pushback from insurers, given that there is no alternative to push back toward, and modeled peak U.S. sales of $160 million a year by 2040. In this market, unmet need is not a brake on price. It is the pricing power. And the voucher stacked on top turns the incentive into cash: Zevra sold one for $150 million in April 2025, Abeona sold one for $155 million that July, and the record is AbbVie’s $350 million purchase back in 2015. So a therapy for a few hundred Americans arrived alongside a resellable federal coupon worth roughly what a mid-size biotech raises in a full funding round. Ionis says it is still deciding whether to sell the voucher or spend it in-house.
Both readings hold. A fatal childhood brain disease that never had a drug now has one that appears to keep children on their feet, built on twenty years of patient chemistry. And the same approval is a clean demonstration of the ultra-rare-disease incentive machine doing precisely what it was designed to do: a premium price a captive market cannot negotiate, and a government voucher resellable for the price of a small acquisition, stacked on top. The breakthrough earns its headline. It should not be allowed to launder the arithmetic.
What decides the verdict is durability, and who pays for it. The open-label extension will show whether the week-61 gait benefit survives to year three and beyond, and that answer, not the approval, tells parents and payers what $1.14 million a year actually bought. Recordati, which took ex-U.S. rights in June for $30 million upfront, will carry the same price question into European regulators. And Ionis’s call on the voucher, sell it or use it, will be the plainest signal yet of how a company that just treated the untreatable weighs the machine against the medicine.
Sources
- FDA – FDA Approves First Drug to Treat Alexander Disease (September 3, 2026)
- Ionis Pharmaceuticals – Zanvastro (zilganersen) approved by the FDA as the first and only disease-modifying treatment for Alexander disease
- MedCity News – FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease (price, patient count, analyst commentary, Recordati license)
- BioSpace – Priority Review Vouchers: By the Numbers
- Zevra Therapeutics – Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (April 2025)
- Abeona Therapeutics – Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (July 2025)
- Ionis Pharmaceuticals – Spinraza (nusinersen) approved in the U.S. to treat spinal muscular atrophy
- Ionis Pharmaceuticals – FDA approves Qalsody (tofersen) as the first treatment targeting a genetic cause of ALS